Sutro Biopharma Inc
NASDAQ:STRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lopez Holdings Corp
XPHS:LPZ
|
PH |
Sutro Biopharma Inc
Accrued Liabilities
Sutro Biopharma Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sutro Biopharma Inc
NASDAQ:STRO
|
Accrued Liabilities
$57m
|
CAGR 3-Years
21%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
Sutro Biopharma Inc
Glance View
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
See Also
What is Sutro Biopharma Inc's Accrued Liabilities?
Accrued Liabilities
57m
USD
Based on the financial report for Dec 31, 2025, Sutro Biopharma Inc's Accrued Liabilities amounts to 57m USD.
What is Sutro Biopharma Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
45%
Over the last year, the Accrued Liabilities growth was 10%. The average annual Accrued Liabilities growth rates for Sutro Biopharma Inc have been 21% over the past three years , 45% over the past five years .
